IGC’s Drug Candidate for Alzheimer’s Potentially Presents New Molecular Pathway for THC to Inhibit Aβ40 Production
IGC Builds Team Adding Industry Leader Dr. Chuanhai Cao, an expert on THC-Based Alzheimer’s Disease Treatments
IGC Featured in "Potential Blockbuster Treatment for Alzheimer's Disease Stands Out Among Medical Cannabis Companies"
IGC Appoints Medical Advisor Craig Cheifetz, M.D. to Consult on the Development of Cannabis- Based, Combination Therapies
IGC Acquires 10% Stake in 1,000-Room Luxury Hotel Development Project in Genting Highlands, Malaysia